Frontier Medicines
Curated by SignalDeveloper of a bioinformatics platform for drug development and chemoproteomics
Overview
Developer of a bioinformatics platform for drug development and chemoproteomics. The proprietary chemoproteomics platform uses machine learning technology to analyze proteins to identify active binding sites as drug targets to treat diseases. The platform consists of a database of hotspots in proteins, a library of chemically diverse compounds, and a novel approach to protein degradation. It ofefrs a lead program FMC-376, which is a novel dual inhibitor of both active and inactive KRASG12 for non-small cell lung, colorectal, and pancreatic cancers.
Key facts
- Founded
- 2018
- Headquarters
- San Francisco, United States
- Stage
- Sign up to view
- Industry
- Health Technology
Business model
- 4 products and services
- Sign up to view
Contact
- Primary office
- Sign up to view
- Sign up to view
- Phone
- Sign up to view
Open roles
17 rolesDirector/Sr. Director, Quality Assurance (GCP/GMP)
Boston, MA · On-site · Volunteer
VP, Clinical Pharmacology
Boston, MA · On-site · Volunteer
AI Cheminformatics Engineer I
South San Francisco, CA · On-site · Volunteer